Answers are grounded in this paper and cite their sources.
Cerebrovascular diseases arise from diverse acute and chronic vascular insults, yet mitochondrial dysfunction is often framed primarily as bioenergetic failure or a downstream consequence of tissue injury. This view underestimates the role of mitochondria as signalling organelles that couple metabolic stress to sterile inflammation, neurovascular homeostatic failure and repair. Accordingly, this review addresses three questions: which mitochondrial stress programmes are shared versus disease-specific; how their consequences vary by neurovascular cell type, anatomical niche and disease phase; and which biomarkers or interventions have sufficient human and mechanistic support to justify translational development. This critical narrative review synthesises mechanistic, single-cell and spatial, human biospecimen, metabolic-monitoring and translational evidence across ischaemic stroke and reperfusion injury, intracerebral and subarachnoid haemorrhage, cerebral small-vessel disease, vascular cognitive impairment, and selected genetic or structural vasculopathies. Targeted PubMed searches, including MEDLINE-indexed literature, were updated through 28 September 2026 and supplemented by citation chaining. Evidence was organised by mitochondrial stress state, neurovascular cell type, disease phase, anatomical niche and translational readiness. We propose a spatiotemporal mitochondrial stress-state continuum spanning adaptive homeostasis, inflammatory transition, decompensated failure, and resolution and repair. Transient mitochondrial reactive oxygen species, metabolic reprogramming, biogenesis and appropriately tuned mitochondrial quality control can preserve cellular resilience, whereas persistent respiratory-chain impairment, calcium overload, permeability transition and defective quality control favour mitochondrial danger-signal release and innate immune activation. Mitochondrial DNA, cardiolipin, ATP, N-formyl peptides and extracellular mitochondrial material are decoded through cGAS–STING, NLRP3, AIM2, TLR9 and related pathways in a cell- and phase-dependent manner. Responses differ across endothelium, mural cells, resident and infiltrating myeloid cells, astrocytes, oligodendroglial lineage cells and neurons. Intercellular mitochondrial transfer can support metabolic rescue or propagate inflammatory injury depending on donor, cargo, recipient and timing. Human blood, cerebrospinal fluid, perihaematomal tissue and local metabolic studies demonstrate measurable mitochondrial abnormalities, but no single biomarker currently offers sufficient disease specificity, external validation or treatment-selection utility. Translation therefore requires alignment of target cell, mitochondrial state, intervention window, delivery route and pharmacodynamic target engagement. Mitochondrial abnormalities should not be treated as a single therapeutic axis. The most credible translational path is to identify a measurable, disease- and phase-specific mitochondrial state, link it to a defined neurovascular cell or compartment, demonstrate target engagement, and test intervention as an adjunct to established cerebrovascular care. Longitudinal human validation and state-enriched trials are now required to determine whether this framework can improve prediction or treatment selection.
No takes yet. Share an insight, caveat, or question.
Zhou et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: